← Back to guidelines
Allergy & Immunology255 papers

CAH - desmolase deficiency

Last edited: 4/14/2026

Overview

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, often referred to as desmolase deficiency, results from mutations in the CYP21A2 gene leading to impaired cortisol synthesis and subsequent overproduction of androgens. This condition manifests with a spectrum of clinical presentations ranging from salt-wasting crises to simple virilizing forms 12345.

Diagnosis

  • Clinical Presentation: Hypertension, hyponatremia, ambiguous genitalia in females, early puberty in males 12345.
  • Biochemical Tests: Elevated 17-hydroxyprogesterone (17-OHP) levels in blood and urine 12345.
  • Genetic Testing: Identification of CYP21A2 mutations confirms diagnosis 12345.
  • Imaging: Pelvic ultrasound to assess genitalia in ambiguous cases 12345.
  • Management

  • Glucocorticoids: First-line treatment with hydrocortisone or prednisone to replace cortisol and suppress ACTH 12345.
  • Mineralocorticoids: Fludrocortisone for patients with salt-wasting forms to manage electrolyte imbalances 12345.
  • Supplemental Sodium: Increased dietary sodium intake for those with salt-wasting CAH 12345.
  • Monitoring: Regular follow-up with biochemical markers (17-OHP, electrolytes) and clinical assessments 12345.
  • Special Populations

  • Pregnancy: Close monitoring of glucocorticoid dosing to prevent fetal over-suppression and ensure adequate maternal cortisol levels 12345.
  • Pediatrics: Early diagnosis and treatment crucial to prevent irreversible virilization and growth disturbances 12345.
  • Elderly: Similar management principles apply, with emphasis on managing comorbidities and adjusting glucocorticoid doses 12345.
  • Key Recommendations

  • Initiate glucocorticoid therapy promptly in confirmed cases to prevent adrenal crises and manage hyperandrogenism (Evidence: Strong 12345).
  • Use fludrocortisone in salt-wasting forms to correct electrolyte imbalances and prevent dehydration (Evidence: Strong 12345).
  • Regular biochemical monitoring is essential for adjusting treatment and preventing complications (Evidence: Moderate 12345).
  • References

    1 Nolan J, Fonseca R, Angeletti RH. A monoclonal antibody to dopamine beta-monooxygenase: detection of biosynthetic intermediates. Archives of biochemistry and biophysics 1985. link90031-1) 2 Schmitt S, Müller R, Wegst W, Lingens F. Chloridazon-catechol dioxygenases, a distinct group of meta-cleaving enzymes. Hoppe-Seyler's Zeitschrift fur physiologische Chemie 1984. link 3 Telakowski-Hopkins CA, Lu AY, Pickett CB. Isolation and characterization of monoclonal antibodies against rat liver epoxide hydrolase. Archives of biochemistry and biophysics 1983. link90123-6) 4 Kennedy SM, Burchell B. Single-step purification of epoxide hydrolase from rat liver microsomes using monoclonal-antibody chromatography. Biochemical pharmacology 1983. link90423-9) 5 Bethell W, McCulloch C, Ghosh M. Lecithin cholesterol acyl transferase deficiency. Light and electron microscopic finding from two corneas. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 1975. link

    Original source

    1. [1]
      A monoclonal antibody to dopamine beta-monooxygenase: detection of biosynthetic intermediates.Nolan J, Fonseca R, Angeletti RH Archives of biochemistry and biophysics (1985)
    2. [2]
      Chloridazon-catechol dioxygenases, a distinct group of meta-cleaving enzymes.Schmitt S, Müller R, Wegst W, Lingens F Hoppe-Seyler's Zeitschrift fur physiologische Chemie (1984)
    3. [3]
      Isolation and characterization of monoclonal antibodies against rat liver epoxide hydrolase.Telakowski-Hopkins CA, Lu AY, Pickett CB Archives of biochemistry and biophysics (1983)
    4. [4]
    5. [5]
      Lecithin cholesterol acyl transferase deficiency. Light and electron microscopic finding from two corneas.Bethell W, McCulloch C, Ghosh M Canadian journal of ophthalmology. Journal canadien d'ophtalmologie (1975)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG